Wechselwirkungen · Zykadia
Zykadia 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-131756 · Präparat HOS-097124
In clinical studies, QT prolongation was observed with ceritinib. Therefore, ceritinib should be used with caution in patients who have or may develop prolongation of the QT interval, including those patients taking anti-arrhythmic medicinal products such as class I (e.g. quinidine, procainamide, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) anti-arrhythmics or other medicinal products that may lead to QT prolongation such as domperidone, droperidol, chloroquine, halofantrine, clarithromycin, haloperidol, methadone, cisapride and moxifloxacin. Monitoring of the QT interval is indicated in the event of combinations of such medicinal products (see sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) cisapride (HOS-085610) methadone (HOS-086198) droperidol (HOS-087801) dofetilide (HOS-085598) halofantrine (HOS-085606) ibutilide (HOS-085599) quinidine (HOS-085593) domperidone (HOS-114656) lead (HOS-085592) disopyramide (HOS-085595) procainamide (HOS-086617) clarithromycin (HOS-084517) moxifloxacin (HOS-085604) haloperidol (HOS-085602) amiodarone (HOS-085596) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-29T12:25:00Z · SHA-256 0b1dbf25bbec546abc5492b7ae4f6a782b99bf34d000b6651bc6bf57cbe85e06 · Passage 40eae0cde8e04371791e5e3fd69248b7ef61350ffe5b042411f9596daa975d64 · Zeichen 7490–8197 im Abschnitt